loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
IPOLogoImag

Q LINE BIOTECH IPO

CLOSED

IPO Details

21th May 2026
25th May 2026
400
₹ 2,74,400
₹ 326-343
₹ 214 Crore

Issue timeline

  • 21-25 May 2026
  • 26-May-2026
  • 27-May-2026
  • 27-May-2026
  • 29-May-2026

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

Q-Line Biotech Limited develops, manufactures, and distributes a wide range of medical reagents, consumables, and diagnostic equipment. Serving diagnostic service providers, hospitals, and medical colleges directly and through an extensive distributor network, the company has built its brand over a 12-year track record driven by robust in-house R&D and strict quality assurance.

The company operates across major in-vitro diagnostics (IVD) and pathology segments, including Clinical Chemistry, Haematology, Immunodiagnostics, and Molecular Diagnostics. Backed by a manufacturing team of 126 employees and 223 third-party workers, the company achieved an aggregate annual installed capacity of 1.4 million kits and 1,200 Selectra Machines by December 2025. Additionally, the firm leverages strategic technical collaborations to produce a specialized range of unpatented Covid-19 testing kits, including RT-PCR and RNA extraction kits.

2010
Saurabh Garg

Objectives

Repayment of certain borrowing availed by the Company, in part or full
To meet working capital requirements
General corporate purposes

Strengths & Risks

Strengths (4)

Advanced R&D and Manufacturing: Operates four production units backed by an active 19-member research team and an ISO-certified diagnostic facility.

Risks (4)

Operational Disruptions: Any manufacturing or R&D shutdowns, stoppages, or slowdowns would directly hurt the company's financial condition and cash flows.

Financials

Industry Overview

  • Strong Market Recovery and Expansion: Following a post-pandemic stabilization, the Indian In-Vitro Diagnostics (IVD) market rebounded to USD 1,677 million in CY25 and is projected to grow at a CAGR of up to 12.2%, reaching USD 2,978 million by CY30.
  • Technological Shift to Point-of-Care: The sector is undergoing a massive transformation driven by automation, AI, and miniaturization, accelerating the growth of the rapid test market toward a projected USD 205 million by CY30 as healthcare shifts from reactive care to home diagnostics.
  • Sustained Demand and Policy Support: Market expansion is fuelled by an aging population, a rising burden of chronic lifestyle diseases, and increasing medical insurance penetration, heavily backed by government initiatives like Make in India and Public-Private Partnership (PPP) models.

Q-Line Biotech IPO FAQs

What is the Q-Line Biotech IPO opening date?

The Q-Line Biotech IPO is scheduled to open for public subscription on May 21, 2026, and close on May 25, 2026.

The price band for Q-Line Biotech IPO has been fixed in the range of ₹326 to ₹343 per equity share.

The minimum lot size for Q-Line Biotech IPO is 400, and the minimum amount required for application is ₹2,74,400, with 2 lots being the minimum application size.

The promoters of the company are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.

The shares are proposed to be listed on the NSE and SME.

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.